Anemia and Inflammation

Completed

• Conditions: Iron Deficiency Anemia; Inflammation
• Interventions: Biological: Dultavax and Vaxigrip

• Registration Number: NCT03618914
• Lead Sponsor: Swiss Federal Institute of Technology

Brief Summary

During inflammation hepcidin concentrations are increased, leading to a decrease in iron absorption. In iron deficiency anemia hepcidin is suppressed due to the activation of erythropoiesis. Whether inflammation or anemia has the stronger effect on hepcidin is uncertain.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-09-15
• Primary Completion: 2018-03-29
• Study Completion: 2018-06-30
• Study First Submitted: 2018-07-23
• Status Verified: 2018-08
• Study First Submitted QC: 2018-08-06
• Study First Posted: 2018-08-07
• Last Update Submitted: 2018-08-20
• Last Update Posted: 2018-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

• BMI <27.5kg/m2
• body weight <70kg
• either non-anemic (Hb>12.5g/dl) or anemic (Hb between 8-12 g/dl and ferritin <15ng/ml)

Exclusion Criteria

• pregnant or lactating
• chronic disease
• smoking
• inflammation defined as CRP<5mg/L; AGP<1g/L

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
anemic women	Dultavax and Vaxigrip	anemia due to iron deficiency
Non-anemic women	Dultavax and Vaxigrip	-

Primary Outcome Measures

Name	Time	Method
Fractional and total iron absorption	14 days after the test meal administered 24 hours after vaccination

Secondary Outcome Measures

Name	Time	Method
Serum Interleukin 6	up to 36 hours	inflammation
Serum ferritin	up to 36 hours	Iron status
Serum CRP	up to 36 hours	inflammation
Serum AGP	up to 36 hours	inflammation
Serum hepcidin	up to 36 hours
Serum transferrin	up to 36 hours	Iron status

Trial Locations

Locations (1)

Ibn Tofail University-CNESTEN; 🇲🇦 Rabat, Morocco